anti vinculin antibody Search Results


93
Developmental Studies Hybridoma Bank anti vinculin
Anti Vinculin, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vinculin/product/Developmental Studies Hybridoma Bank
Average 93 stars, based on 1 article reviews
anti vinculin - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

93
Bioss vinculin
Ligustrazine suppresses hypoxia-induced PMC functions by activating PPAR γ . (a, b) Western blot and qRT-PCR analysis of PPAR γ levels in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. (c) Immunofluorescence analysis of PPAR γ nuclear distribution in hypoxia-induced PMCs treated with 20 μ M ligustrazine for 24 h (200x). (d) Flow cytometry analysis of PPAR γ nuclear translocation in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (e) Western blot analysis of protein expression of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (f, g) FDA staining assay of cell viability in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h (200x). Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. Compared with the ligustrazine group, # P < 0.05 and ## P < 0.01. (h) Western blot analysis of protein expression of migration and adhesion-associated molecules (VCAM-1 and ICAM-1) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (i) Western blot analysis of cytoskeleton protein <t>(vinculin)</t> expression in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (j) Western blot analysis of protein expression of FSP1 in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (k) Western blot analysis of protein expression of ECM-associated molecules (MMP2 and TIMP-1), mesothelial-related phenotypic biomarkers (E-cadherin and cytokeratin 18), and mesenchymal-related phenotypic biomarkers (Snail <t>and</t> <t>α</t> -SMA) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h.
Vinculin, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vinculin/product/Bioss
Average 93 stars, based on 1 article reviews
vinculin - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

94
Bio-Rad anti vinculin antibody
Ligustrazine suppresses hypoxia-induced PMC functions by activating PPAR γ . (a, b) Western blot and qRT-PCR analysis of PPAR γ levels in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. (c) Immunofluorescence analysis of PPAR γ nuclear distribution in hypoxia-induced PMCs treated with 20 μ M ligustrazine for 24 h (200x). (d) Flow cytometry analysis of PPAR γ nuclear translocation in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (e) Western blot analysis of protein expression of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (f, g) FDA staining assay of cell viability in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h (200x). Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. Compared with the ligustrazine group, # P < 0.05 and ## P < 0.01. (h) Western blot analysis of protein expression of migration and adhesion-associated molecules (VCAM-1 and ICAM-1) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (i) Western blot analysis of cytoskeleton protein <t>(vinculin)</t> expression in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (j) Western blot analysis of protein expression of FSP1 in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (k) Western blot analysis of protein expression of ECM-associated molecules (MMP2 and TIMP-1), mesothelial-related phenotypic biomarkers (E-cadherin and cytokeratin 18), and mesenchymal-related phenotypic biomarkers (Snail <t>and</t> <t>α</t> -SMA) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h.
Anti Vinculin Antibody, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vinculin antibody/product/Bio-Rad
Average 94 stars, based on 1 article reviews
anti vinculin antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

93
Boster Bio anti vinculin antibody
Ligustrazine suppresses hypoxia-induced PMC functions by activating PPAR γ . (a, b) Western blot and qRT-PCR analysis of PPAR γ levels in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. (c) Immunofluorescence analysis of PPAR γ nuclear distribution in hypoxia-induced PMCs treated with 20 μ M ligustrazine for 24 h (200x). (d) Flow cytometry analysis of PPAR γ nuclear translocation in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (e) Western blot analysis of protein expression of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (f, g) FDA staining assay of cell viability in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h (200x). Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. Compared with the ligustrazine group, # P < 0.05 and ## P < 0.01. (h) Western blot analysis of protein expression of migration and adhesion-associated molecules (VCAM-1 and ICAM-1) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (i) Western blot analysis of cytoskeleton protein <t>(vinculin)</t> expression in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (j) Western blot analysis of protein expression of FSP1 in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (k) Western blot analysis of protein expression of ECM-associated molecules (MMP2 and TIMP-1), mesothelial-related phenotypic biomarkers (E-cadherin and cytokeratin 18), and mesenchymal-related phenotypic biomarkers (Snail <t>and</t> <t>α</t> -SMA) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h.
Anti Vinculin Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vinculin antibody/product/Boster Bio
Average 93 stars, based on 1 article reviews
anti vinculin antibody - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

94
Boster Bio ma1103
Reagents and tools table
Ma1103, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ma1103/product/Boster Bio
Average 94 stars, based on 1 article reviews
ma1103 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

92
Boster Bio vinculin
Reagents and tools table
Vinculin, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vinculin/product/Boster Bio
Average 92 stars, based on 1 article reviews
vinculin - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

93
Developmental Studies Hybridoma Bank mouse anti metavinculin
Reagents and tools table
Mouse Anti Metavinculin, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti metavinculin/product/Developmental Studies Hybridoma Bank
Average 93 stars, based on 1 article reviews
mouse anti metavinculin - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

92
Boster Bio anti vinculin
Reagents and tools table
Anti Vinculin, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vinculin/product/Boster Bio
Average 92 stars, based on 1 article reviews
anti vinculin - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

90
Boster Bio trif
Fig. 8. Effects of TFE from Folium isatidis on the genes expression <t>of</t> <t>TLR4</t> (a), TRAF6 (b), <t>TRIF</t> (c), I 𝜅B (d) and p65 (e) in lungs tissues of LPS induced ALI mice ( # compared with the control, ∗ compared with LPS, ∗ P < 0.05, ∗ ∗ / ## P < 0.01).
Trif, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trif/product/Boster Bio
Average 90 stars, based on 1 article reviews
trif - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Merck & Co anti-vinculin mouse monoclonal antibody
Fig. 8. Effects of TFE from Folium isatidis on the genes expression <t>of</t> <t>TLR4</t> (a), TRAF6 (b), <t>TRIF</t> (c), I 𝜅B (d) and p65 (e) in lungs tissues of LPS induced ALI mice ( # compared with the control, ∗ compared with LPS, ∗ P < 0.05, ∗ ∗ / ## P < 0.01).
Anti Vinculin Mouse Monoclonal Antibody, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-vinculin mouse monoclonal antibody/product/Merck & Co
Average 90 stars, based on 1 article reviews
anti-vinculin mouse monoclonal antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Merck KGaA mouse anti vinculin

Mouse Anti Vinculin, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti vinculin/product/Merck KGaA
Average 90 stars, based on 1 article reviews
mouse anti vinculin - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Merck & Co vinculin
Effects <t>of</t> <t>si-CD147</t> on FAK and <t>vinculin</t> expression in SMMC-7721 cells . Total cellular protein from SMMC-7721 cells tranfected with siRNA was analyzed by 10% SDS-PAGE and transferred to PVDF membrane prior to immunoblotting. The PVDF membranes were washed and the bands were scanned by Odyssey Infrared Imaging System. The results showed that si-CD147 inhibited FAK and vinculiln expression in SMMC-7721 cells (A). The graph (B) compares scanning signal intensity of FAK and vinculin expression by ImageJ software.
Vinculin, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vinculin/product/Merck & Co
Average 90 stars, based on 1 article reviews
vinculin - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Ligustrazine suppresses hypoxia-induced PMC functions by activating PPAR γ . (a, b) Western blot and qRT-PCR analysis of PPAR γ levels in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. (c) Immunofluorescence analysis of PPAR γ nuclear distribution in hypoxia-induced PMCs treated with 20 μ M ligustrazine for 24 h (200x). (d) Flow cytometry analysis of PPAR γ nuclear translocation in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (e) Western blot analysis of protein expression of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (f, g) FDA staining assay of cell viability in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h (200x). Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. Compared with the ligustrazine group, # P < 0.05 and ## P < 0.01. (h) Western blot analysis of protein expression of migration and adhesion-associated molecules (VCAM-1 and ICAM-1) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (i) Western blot analysis of cytoskeleton protein (vinculin) expression in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (j) Western blot analysis of protein expression of FSP1 in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (k) Western blot analysis of protein expression of ECM-associated molecules (MMP2 and TIMP-1), mesothelial-related phenotypic biomarkers (E-cadherin and cytokeratin 18), and mesenchymal-related phenotypic biomarkers (Snail and α -SMA) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Elucidating the Novel Mechanism of Ligustrazine in Preventing Postoperative Peritoneal Adhesion Formation

doi: 10.1155/2022/9226022

Figure Lengend Snippet: Ligustrazine suppresses hypoxia-induced PMC functions by activating PPAR γ . (a, b) Western blot and qRT-PCR analysis of PPAR γ levels in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. (c) Immunofluorescence analysis of PPAR γ nuclear distribution in hypoxia-induced PMCs treated with 20 μ M ligustrazine for 24 h (200x). (d) Flow cytometry analysis of PPAR γ nuclear translocation in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (e) Western blot analysis of protein expression of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (f, g) FDA staining assay of cell viability in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h (200x). Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. Compared with the ligustrazine group, # P < 0.05 and ## P < 0.01. (h) Western blot analysis of protein expression of migration and adhesion-associated molecules (VCAM-1 and ICAM-1) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (i) Western blot analysis of cytoskeleton protein (vinculin) expression in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (j) Western blot analysis of protein expression of FSP1 in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. (k) Western blot analysis of protein expression of ECM-associated molecules (MMP2 and TIMP-1), mesothelial-related phenotypic biomarkers (E-cadherin and cytokeratin 18), and mesenchymal-related phenotypic biomarkers (Snail and α -SMA) in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h.

Article Snippet: VEGF (sc-57496, Santa Cruz, USA), CTGF (sc-373936, Santa Cruz, USA), vascular cell adhesion molecule-1 (VCAM-1; ab134047, Abcam, USA), intercellular cell adhesion molecular-1 (ICAM-1; sc-8439, Santa Cruz, USA), cofilin (bs-2759R, Bioss, China), phospho-cofilin (p-cofilin, bs-20261R, Bioss, China), fibroblast-specific protein 1 (FSP1; bs-3759R, Bioss, China), matrix metalloproteinases 2 (MMP2; bs-4605R, Bioss, China), tissue inhibitor of metalloproteinases-1 (TIMP-1; bs-0415R, Bioss, China), E-cadherin (bs-1519R, Bioss, China), cytokeratin 18 (bs-2043R, Bioss, China), Snail (bs-1371R, Bioss, China), α -smooth muscle actin ( α -SMA; bs-10196R, Bioss, China), F-actin (FITC-conjugated phalloidin, C1033, Beyotime, China), vinculin (bs-6640R, Bioss, China), peroxisome proliferator-activated receptor γ (PPAR γ ; bs-4590R, Bioss, China), lamin B1 (sc-377000, Santa Cruz, USA), β -actin (CW0096M, CWBIO, China), and hypoxia-inducible factor 1 α (HIF-1 α ; sc-71247, Santa Cruz, USA) were used.

Techniques: Western Blot, Quantitative RT-PCR, Immunofluorescence, Flow Cytometry, Translocation Assay, Expressing, Staining, Migration

The suppression effect of ligustrazine is achieved by the activated PPAR γ on the transrepression of SMRT-mediated HIF-1 α . (a) Western blot analysis of protein expression of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with KC7F2 for 24 h. (b, c) FDA staining assay of cell viability in hypoxia-induced PMCs treated with KC7F2 for 24 h (200x). Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. (d) Western blot analysis of protein expression of migration and adhesion-associated molecules (VCAM-1 and ICAM-1) in hypoxia-induced PMCs treated with KC7F2 for 24 h. (e) Western blot analysis of cytoskeleton protein (vinculin) expression in hypoxia-induced PMCs treated with KC7F2 for 24 h. (f) Western blot analysis of protein expression of FSP1 in hypoxia-induced PMCs treated with KC7F2 for 24 h. (g) Western blot analysis of protein expression of ECM-associated molecules (MMP2 and TIMP-1), mesothelial-related phenotypic biomarkers (E-cadherin and cytokeratin 18), and mesenchymal-related phenotypic biomarkers (Snail and α -SMA) in hypoxia-induced PMCs treated with KC7F2 for 24 h. (h, i) qRT-PCR and Western blot analysis of HIF-1 α levels in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. Compared with the ligustrazine group, # P < 0.05 and ## P < 0.01. (j, k) qRT-PCR analysis of mRNA levels of SMRT and NCoR in hypoxia-induced HPMCs after different transfection for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. (l) qRT-PCR analysis of mRNA levels of HIF-1 α in hypoxia-induced HPMCs treated with 20 μ M ligustrazine and/or with different transfection for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. Compared with the ligustrazine group, # P < 0.05 and ## P < 0.01. (m) Western blot analysis of protein expression of HIF-1 α in hypoxia-induced HPMCs treated with 20 μ M ligustrazine and/or with different transfection for 24 h.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Elucidating the Novel Mechanism of Ligustrazine in Preventing Postoperative Peritoneal Adhesion Formation

doi: 10.1155/2022/9226022

Figure Lengend Snippet: The suppression effect of ligustrazine is achieved by the activated PPAR γ on the transrepression of SMRT-mediated HIF-1 α . (a) Western blot analysis of protein expression of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with KC7F2 for 24 h. (b, c) FDA staining assay of cell viability in hypoxia-induced PMCs treated with KC7F2 for 24 h (200x). Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. (d) Western blot analysis of protein expression of migration and adhesion-associated molecules (VCAM-1 and ICAM-1) in hypoxia-induced PMCs treated with KC7F2 for 24 h. (e) Western blot analysis of cytoskeleton protein (vinculin) expression in hypoxia-induced PMCs treated with KC7F2 for 24 h. (f) Western blot analysis of protein expression of FSP1 in hypoxia-induced PMCs treated with KC7F2 for 24 h. (g) Western blot analysis of protein expression of ECM-associated molecules (MMP2 and TIMP-1), mesothelial-related phenotypic biomarkers (E-cadherin and cytokeratin 18), and mesenchymal-related phenotypic biomarkers (Snail and α -SMA) in hypoxia-induced PMCs treated with KC7F2 for 24 h. (h, i) qRT-PCR and Western blot analysis of HIF-1 α levels in hypoxia-induced PMCs treated with 20 μ M ligustrazine and/or 1 μ M GW9662 for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. Compared with the ligustrazine group, # P < 0.05 and ## P < 0.01. (j, k) qRT-PCR analysis of mRNA levels of SMRT and NCoR in hypoxia-induced HPMCs after different transfection for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. (l) qRT-PCR analysis of mRNA levels of HIF-1 α in hypoxia-induced HPMCs treated with 20 μ M ligustrazine and/or with different transfection for 24 h. Compared with the control, ∗ P < 0.05 and ∗∗ P < 0.01. Compared with the ligustrazine group, # P < 0.05 and ## P < 0.01. (m) Western blot analysis of protein expression of HIF-1 α in hypoxia-induced HPMCs treated with 20 μ M ligustrazine and/or with different transfection for 24 h.

Article Snippet: VEGF (sc-57496, Santa Cruz, USA), CTGF (sc-373936, Santa Cruz, USA), vascular cell adhesion molecule-1 (VCAM-1; ab134047, Abcam, USA), intercellular cell adhesion molecular-1 (ICAM-1; sc-8439, Santa Cruz, USA), cofilin (bs-2759R, Bioss, China), phospho-cofilin (p-cofilin, bs-20261R, Bioss, China), fibroblast-specific protein 1 (FSP1; bs-3759R, Bioss, China), matrix metalloproteinases 2 (MMP2; bs-4605R, Bioss, China), tissue inhibitor of metalloproteinases-1 (TIMP-1; bs-0415R, Bioss, China), E-cadherin (bs-1519R, Bioss, China), cytokeratin 18 (bs-2043R, Bioss, China), Snail (bs-1371R, Bioss, China), α -smooth muscle actin ( α -SMA; bs-10196R, Bioss, China), F-actin (FITC-conjugated phalloidin, C1033, Beyotime, China), vinculin (bs-6640R, Bioss, China), peroxisome proliferator-activated receptor γ (PPAR γ ; bs-4590R, Bioss, China), lamin B1 (sc-377000, Santa Cruz, USA), β -actin (CW0096M, CWBIO, China), and hypoxia-inducible factor 1 α (HIF-1 α ; sc-71247, Santa Cruz, USA) were used.

Techniques: Western Blot, Expressing, Staining, Migration, Quantitative RT-PCR, Transfection

Reagents and tools table

Journal: The EMBO Journal

Article Title: An EpCAM/Trop2 mechanostat differentially regulates collective behaviour of human carcinoma cells

doi: 10.1038/s44318-024-00309-9

Figure Lengend Snippet: Reagents and tools table

Article Snippet: vinculin , Boster Bio , MA1103 , Mouse , 1:100.

Techniques: Control, Recombinant, Plasmid Preparation, Modification, Western Blot, Electron Microscopy, Saline

Fig. 8. Effects of TFE from Folium isatidis on the genes expression of TLR4 (a), TRAF6 (b), TRIF (c), I 𝜅B (d) and p65 (e) in lungs tissues of LPS induced ALI mice ( # compared with the control, ∗ compared with LPS, ∗ P < 0.05, ∗ ∗ / ## P < 0.01).

Journal: Pharmacological Research - Modern Chinese Medicine

Article Title: The pharmaceutical applications of total flavonoids extract from Isatis tinctoria L. leaves

doi: 10.1016/j.prmcm.2022.100122

Figure Lengend Snippet: Fig. 8. Effects of TFE from Folium isatidis on the genes expression of TLR4 (a), TRAF6 (b), TRIF (c), I 𝜅B (d) and p65 (e) in lungs tissues of LPS induced ALI mice ( # compared with the control, ∗ compared with LPS, ∗ P < 0.05, ∗ ∗ / ## P < 0.01).

Article Snippet: Antibodies against TLR4, RAF6, TRIF, NF- κB p65, p-NF- κB p65, I κB α, p-I κB α and β-actin were urchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and econdary antibodies were obtained from Wuhan Boster Biological Techology., Ltd (Wuhan, China).

Techniques: Expressing, Control

Fig. 9. Effects of TFE from Folium isatidis on the proteins expression of TLR4 (a), TRAF6 (b), TRIF (c), I 𝜅B (d), p-I 𝜅B (e), p65 (f) and p-p65 (g) in lungs tissues of LPS induced ALI mice ( # compared with the cntrol, ∗ compared with LPS, ∗ P < 0.05, ∗ ∗ / ## P < 0.01).

Journal: Pharmacological Research - Modern Chinese Medicine

Article Title: The pharmaceutical applications of total flavonoids extract from Isatis tinctoria L. leaves

doi: 10.1016/j.prmcm.2022.100122

Figure Lengend Snippet: Fig. 9. Effects of TFE from Folium isatidis on the proteins expression of TLR4 (a), TRAF6 (b), TRIF (c), I 𝜅B (d), p-I 𝜅B (e), p65 (f) and p-p65 (g) in lungs tissues of LPS induced ALI mice ( # compared with the cntrol, ∗ compared with LPS, ∗ P < 0.05, ∗ ∗ / ## P < 0.01).

Article Snippet: Antibodies against TLR4, RAF6, TRIF, NF- κB p65, p-NF- κB p65, I κB α, p-I κB α and β-actin were urchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and econdary antibodies were obtained from Wuhan Boster Biological Techology., Ltd (Wuhan, China).

Techniques: Expressing

Fig. 10. Regulation of TFE from Folium isatidis on TLR4-TRIF-NF- 𝜅B signaling pathway in LPS induced ALI mice.

Journal: Pharmacological Research - Modern Chinese Medicine

Article Title: The pharmaceutical applications of total flavonoids extract from Isatis tinctoria L. leaves

doi: 10.1016/j.prmcm.2022.100122

Figure Lengend Snippet: Fig. 10. Regulation of TFE from Folium isatidis on TLR4-TRIF-NF- 𝜅B signaling pathway in LPS induced ALI mice.

Article Snippet: Antibodies against TLR4, RAF6, TRIF, NF- κB p65, p-NF- κB p65, I κB α, p-I κB α and β-actin were urchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and econdary antibodies were obtained from Wuhan Boster Biological Techology., Ltd (Wuhan, China).

Techniques:

Journal: Cell Reports

Article Title: SIN3A histone deacetylase action counteracts MUS81 to promote stalled fork stability

doi: 10.1016/j.celrep.2024.113778

Figure Lengend Snippet:

Article Snippet: Mouse anti Vinculin , Merk , Cat#V9264; RRID: AB_10603627.

Techniques: Recombinant, Control, Protease Inhibitor, Imaging, Reverse Transcription, Plasmid Preparation, Software, Magnetic Beads, Blocking Assay, In Situ, Western Blot, Membrane

Effects of si-CD147 on FAK and vinculin expression in SMMC-7721 cells . Total cellular protein from SMMC-7721 cells tranfected with siRNA was analyzed by 10% SDS-PAGE and transferred to PVDF membrane prior to immunoblotting. The PVDF membranes were washed and the bands were scanned by Odyssey Infrared Imaging System. The results showed that si-CD147 inhibited FAK and vinculiln expression in SMMC-7721 cells (A). The graph (B) compares scanning signal intensity of FAK and vinculin expression by ImageJ software.

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Downregulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells

doi: 10.1186/1756-9966-27-50

Figure Lengend Snippet: Effects of si-CD147 on FAK and vinculin expression in SMMC-7721 cells . Total cellular protein from SMMC-7721 cells tranfected with siRNA was analyzed by 10% SDS-PAGE and transferred to PVDF membrane prior to immunoblotting. The PVDF membranes were washed and the bands were scanned by Odyssey Infrared Imaging System. The results showed that si-CD147 inhibited FAK and vinculiln expression in SMMC-7721 cells (A). The graph (B) compares scanning signal intensity of FAK and vinculin expression by ImageJ software.

Article Snippet: After being blocked with 5% (w/v) Odyssey blocking buffer (Li-COR Bioscience), the blots were incubated for overnight with antibodies directed against CD147 (BD Pharmingen), FAK(Sigma Aldrich, America) and vinculin (Merck Calbiochem) at 4°C.

Techniques: Expressing, SDS Page, Western Blot, Imaging, Software